Piramal Pharma Limited Earnings Summary — Q4 FY2026
Piramal Pharma Returns to Minimal Operating Profit but Posts Net Loss Amid High Tax and Non-Operating Costs
Key Takeaways
- Revenue showed a strong seasonal jump of 28.6% QoQ to 2,751.77 Cr, though remained flat YoY.
- Operating Profit Margin (OPM) recovered to 16.74% from single digits in previous quarters, yet trailed the 20.37% achieved in March 2025.
- The company reported a consolidated Net Loss of 8.83 Cr, heavily impacted by an unusually high tax rate of 120.53%.
- Other Income turned significantly negative (-116.14 Cr) in Q4, acting as a major drag on the bottom line.
- Inventory levels have surged to 7,552 Cr by fiscal year-end, indicating substantial capital lock-up.
- Interest costs remain high at 82.99 Cr for the quarter, though slightly lower than previous periods.
- The company continues to face high depreciation charges (218.38 Cr) following heavy capital expenditure cycles.
- Year-to-date performance remains weak with an overall loss for the full fiscal year 2026.
Management Guidance
Management remains focused on integrated projects (40% of new orders) to improve customer stickiness and margins, despite the current volatility in the CDMO sector.
Sentiment Shift
Deteriorating
Outlook
The outlook is cautious. While CDMO demand from regulated markets remains a strength, the company must address high interest costs and inventory levels (345 days) to achieve sustainable bottom-line profitability.
← Back to Piramal Pharma Limited AI analysis
Unlock the full report
Deep-dive sections, financial charts, AI chat and PDF export are available with Premium.
This summary is AI-generated from Piramal Pharma Limited's latest annual report and public disclosures. It is for informational purposes only and is not investment advice.